Core Insights - Skye Bioscience is presenting research on its CB1-inhibitor antibody, nimacimab, at an upcoming conference focused on obesity therapeutics [1] - The presentation will explore nimacimab's efficacy alone and in combination with tirzepatide, as well as its potential as a maintenance therapy after discontinuation of tirzepatide [1][4] Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing new therapeutic pathways for obesity and metabolic health disorders [3] - The company is focused on creating next-generation molecules that modulate G-protein coupled receptors, aiming for first-in-class therapeutics with clinical and commercial differentiation [3] Product Details - Nimacimab is a first-in-class, peripherally-restricted monoclonal antibody that inhibits the CB1 receptor without penetrating the central nervous system, potentially reducing neuropsychiatric side effects [2] - It acts independently of the GLP-1 pathway and has shown additive effects when combined with incretin-based therapies in both preclinical and clinical studies [2] Clinical Trials - Skye is conducting a Phase 2a clinical trial for nimacimab in obesity, which also assesses its combination with a GLP-1R agonist, Wegovy® [3] - The trial is registered under ClinicalTrials.gov with the identifier NCT06577090 [3]